Oral insulin

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Kalra, Sanjay ^a   Kalra, Bharti ^a   Agrawal, Navneet ^b  

^a BHARTI HOSPITAL   (India)

^b Diabetes Obesity and Thyroid Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; CAMOSTAT MESILATE; GLYCOCHOLATE SODIUM; HUMAN INSULIN; INSULIN; NANOPARTICLE; NN 1952; ORMD 0801; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG RELEASE; DRUG SCREENING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 78049463130     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-66     Document Type: Review

References (31)

1. Oral insulin 1922-1992: the history of continuous ambition and failure. M Berger, Frontiers in insulin pharmacology Germany: Thieme Publishing Group, Berger M, Gries FA, 1993 144 8
2. Improvement in diabetes processes of care and intermediate outcomes: United States 1988-2002. JB Saadine B Cadwell EB Gregg,, et al. Ann Intern Med 2006 144 465 474 16585660
3. Oral insulin and buccal insulin: a critical reappraisal. L Heinemann Y Jacques, J Diabetes Sci Technol 2009 3 568 584 20144297
4. Beta-cell failure in diabetes and preservation by clinical treatment. BL Wajchenberg, Endocr Rev 2007 28 187 218 10.1210/10.1210/er.2006-0038 17353295
5. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. JS Skyler JP Krischer J Wolfsdorf,, et al. Diabetes Care 2005 28 1353 1357 10.2337/diacare.28.7.1630 15920051
6. Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. I Bergerot GA Arreaza MJ Cameron,, et al. Diabetes 1999 48 1720 1729 10.2337/diabetes.48.9.1720 10480600
7. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. IM Stratton Al Adler HAW Neil,, et al. BMJ 2000 405 412 10.1136/bmj.321.7258.405 10938048 (Pubitemid 30609442)
8. Oral insulin - a review of current status. H Iyer A Khedkar M Verma, Diabetes, Obesity and Metabolism 2010 12 179 185 10.1111/j.1463-1326.2009.01150. x
9. Oral protein delivery. W Wang, J Drug Target 1996 4 195 232 10.3109/10611869608995624 9010812
10. Oral insulin delivery. GP Carino E Mathiowitz, Adv Drug Deliv Rev 1999 35 249 257 10.1016/S0169-409X(98)00075-1 10837700
11. The physiological rationale for oral insulin administration. E Arbit, Diabetes Technol Ther 2004 6 510 517 10.1089/1520915041705929 15321008
12. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. TJ Aspden JD Mason NS Jones, J Pharm Sci 1997 86 509 513 10.1021/js960182o 9109057
13. Biologically erodible microspheres as potential oral drug delivery systems. E Mathiowitz JS Jacob YS Jong,, et al. Nature 1997 386 410 414 10.1038/386410a0 9121559
14. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as oral carrier. C Damge C Michael M Aprahamian P Couvreur, Diabetes 1988 37 247 251 10.2337/diabetes.37.2.246
15. Calcium alginate microparticles for oral administration. I: effect of sodium alginate type on drug release and drug entrapment efficiency. S Takka F Acarturk, J Microencapsul: Micro Nano Carriers 1999 16 275 290 (Pubitemid 29191812)
16. Beta cyclodextrin-insulinencapsulated chitosan/alginate matrix: oral delivery system. L Rowsen Moses KJ Dileep CP Sharma, J Appl Polym Sci 2000 75 1089 1096 10.1002/(SICI)1097-4628(20000228)75:9<1089::AID-APP1>3.0.CO;2-5
17. Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats. G Dapergolas G Gregoriadis, Lancet 1976 2 824 827 10.1016/S0140-6736(76)91209-5 61498
18. Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake. J Pappo TH Ermak, Clin Exp Immunol 1989 76 144 148 2661061
19. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. A Yamamoto T Taniguchi K Rikyuu,, et al. Pharm Res 1994 11 1496 1500 10.1023/A:1018968611962 7855059 (Pubitemid 24339662)
20. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. S Clement JG Still G Kosutic,, et al. Diabetes Technol Ther 2002 4 459 466 10.1089/ 152091502760306544 12396740
21. The oral absorption of cefoxitin from oil and emulsion vehicles in rats. KJ Palin AJ Phillips A Ning, Int J Pharm 1986 33 99 104 10.1016/0378-5173(86) 90043-8 (Pubitemid 17197793)
22. Modulation of intestinal tight junctions zona occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. A Fasano S Uzzau, J Clin Invest 1997 99 1158 1164 10.1172/JCI119271 9077522
23. Oral insulin: A comparison with subcutaneous regular human insulin in patients with type 2. C Kaptiza E Zijlstra L Heinemann MC Castelli G Riley T Heise, Diabetes Care 2010 33 6 1288 1290 10.2337/dc09-1807 20185734
24. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. A Khedkar H Iyer A Anand M Verma S Krishnamurthy Savale,, et al. Diabetes, Obesity and Metabolism 2010 12 659 664 10.1111/j.1463-1326.2010.01213.x
25. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. JA Scarlett RS Gray J Griffin JM Olefsky OG Kolterman, Diabetes Care 1982 5 353 363 6759075
26. Can insulin resistance be reversed by insulin therapy? L Zhao D Sun F Cao T Yin H Wang, Med Hypotheses 2009 72 34 35 10.1016/j.mehy.2008.07.050 18809262
27. Early evaluation of a novel oral insulin delivery system in healthy volunteers. J Phillips DL Russel-Jones J Wright A Brackenridge R New G Bansal, Diabetes 2004 53 Suppl 2 113
28. Comparison of an oral insulin (Capsulin) and Actrapid during an isoglycemic clamp study in persons with type 2 diabetes. S Luzio G Dunseath A Lockett TP Broke-Smith RR New D Owens, Diabetes 2008 56 Suppl 1 10
29. A 2-week randomized active comparator study of two HDV-Insulin routes (SC and oral) and SC human insulin in patients with type 1 diabetes. S Schwartz B Geho L Rosenberg J Lau, Diabetes 2008 57 Suppl 1 124
30. Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon Preprandial Administration. R Eldor E Ehud Arbit Y Miteva R Freier M Kidron, Poster, ADA, Orlando 2010
31. A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes This study has been completed. Study NCT01028404 http://clinicaltrials.gov/ct2/show/study/NCT01028404